[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 22, 1992

Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease

Author Affiliations

From the Departments of Urology (Drs Carter and Walsh) and Laboratory Medicine (Dr Chan), The Johns Hopkins University School of Medicine, James Buchanan Brady Urological Institute, The Johns Hopkins Hospital; and the Laboratory of Clinical Physiology (Dr Andres) and the Longitudinal Studies Branch (Drs Pearson, Metter, Brant, and Fozard), Gerontology Research Center, National Institute on Aging, Baltimore, Md.

JAMA. 1992;267(16):2215-2220. doi:10.1001/jama.1992.03480160073037

Objective.  ——To evaluate longitudinal changes in prostate-specific antigen (PSA) levels in men with and without prostate disease.

Design.  —Case-control study of men with and without prostate disease who were participants in a prospective aging study.

Setting.  —Gerontology Research Center of the National Institute on Aging; the Baltimore (Md) Longitudinal Study of Aging.

Patients.  —Sixteen men with no prostate disease (control group), 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH), and 18 men with a histologic diagnosis of prostate cancer.

Outcome Measures.  —Multiple PSA and androgen determinations on serum samples obtained from 7 to 25 years prior to histologic diagnosis or exclusion of prostate disease.

Results.  —Changes in androgen levels with age did not differ between groups. Control subjects did not show a significant change in PSA levels with age. There was a significant difference in the age-adjusted rate of change in PSA levels between groups (prostate cancer>BPH>control; P<.01). At 5 years before diagnosis when PSA levels did not differ between subjects with BPH and prostate cancer, rate of change in PSA levels (0.75 μg/L per year) was significantly greater in subjects with prostate cancer compared with control subjects and subjects with BPH. Also, rate of change in PSA levels distinguished subjects with prostate cancer from subjects with BPH and control subjects with a specificity of 90% and 100%, respectively.

Conclusions.  —The most significant factor affecting serum PSA levels with age is the development of prostate disease. Rate of change in PSA levels may be a sensitive and specific early clinical marker for the development of prostate cancer.(JAMA. 1992;267:2215-2220)